Manufacturers discontinue development of sarizotan for Rett syndrome

Data from the pivotal Phase II/III STARS trial of this 5-HT1A receptor agonist and D2 receptor antagonist failed to show an improvement in reduction in episodes of apnoea during waking time versus placebo

Source:

PharmaTimes